Azadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, Patricia Jaaks, Claire Crafter, Howard Lightfoot, Marta Milo, Katrina McCarten, David F Jenkins, Dieudonne van der Meer, James T Lynch, Syd Barthorpe, Courtney L Andersen, Simon T Barry, Alexandra Beck, Justin Cidado, Jacob A Gordon, Caitlin Hall, James Hall, Iman Mali, Tatiana Mironenko, Kevin Mongeon, James Morris, Laura Richardson, Paul D Smith, Omid Tavana, Charlotte Tolley, Frances Thomas, Brandon S Willis, Wanjuan Yang, Mark J O'Connor, Ultan McDermott, Susan E Critchlow, Lisa Drew, Stephen E Fawell, Jerome T Mettetal, Mathew J Garnett
UNLABELLED: Oncology drug combinations can improve therapeutic responses and increase treatment options for patients. The number of possible combinations is vast and responses can be context-specific. Systematic screens can identify clinically relevant, actionable combinations in defined patient subtypes. We present data for 109 anticancer drug combinations from AstraZeneca's oncology small molecule portfolio screened in 755 pan-cancer cell lines. Combinations were screened in a 7 × 7 concentration matrix, with more than 4 million measurements of sensitivity, producing an exceptionally data-rich resource...
March 8, 2024: Cancer Discovery